TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1918275
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without urokinase (control group, n = 32)
Study: 1918275
Drug: Intravenous urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous urokinase (UK) (UK group, n = 66)
Study: 1918275
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without urokinase (control group, n = 68)
Study: 1918275
Drug: Intravenous urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous urokinase (UK) (UK group, n = 10)
Study: 1918275
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without urokinase (control group, n = 22)
Study: 6130665
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of ordinary therapy until planned cholecystectomy under neurolept anaesthesia (n = 13)
Study: 6130665
Drug: 4-day gradual
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day gradual withdrawal of beta-receptor blockers (n = 13)
Study: 31163519
Drug: Methylprednisolone combined
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone combined with peripheral vestibular rehabilitation therapy
Study: 9649009
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (various regimens including intravenous mitomycin plus 5‐fluorouracil, oral 5‐FU, intravenous methotrexate plus 5‐FU, intravenous cisplatin plus 5‐FU, hepatic arterial infusion of 5‐FU plus oral 5‐FU)
Study: 9649009
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no postoperative chemotherapy)
Study: 7517720
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) as a single agent before conventional remission induction therapy
Study: 23517517
Drug: Daily handwashing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily handwashing with soap, daily brushing with fluoride toothpaste, biannual deworming with 400 mg albendazole (Essential Health Care Program [EHCP])
Study: 23517517
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (external concurrent control)
Study: 16783467
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate of IGIV-C, 10% at 0.14 mL/kg/min
Study: 16783467
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate of IGIV-C, 10% at 0.08 mL/kg/min (standard rate)
Study: 16783467
Drug: Both rates
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both rates of infusion (0.08 mL/kg/min and 0.14 mL/kg/min)
Study: 16783467
Drug: Increased rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased rate of infusion of IGIV-C, 10%
Study: 16783467
Drug: Increased rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased rate of infusion of IGIV-C, 10% at 0.14 mL/kg/min
Study: 7021412
Drug: Kallikrein treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kallikrein treatment
Study: 30190369
Drug: Sorafenib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib + modified FOLFOX (sorafenib 400 mg twice a day for 2 weeks, followed by mFOLFOX: 5-FU 1200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, oxaliplatin 85 mg/m2 biweekly)
Study: 25473939
Drug: AZD5423 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5423 (75 or 300 μg) once daily for 7 days
Study: 25473939
Drug: AZD5423 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5423 (300 μg)
Study: 25473939
Drug: AZD5423 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5423 (75 μg)
Study: 25473939
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 μg twice daily)
Study: 24221838
Drug: In-hospital treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital treatments for AMI
Study: 19772502
Drug: Indapamide retard
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide retard therapy for 8 weeks
Study: 17519152
Drug: CARRA/LNG containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: CARRA/LNG containing 0.75 mg LNG per 4 mL of gel
Study: 17519152
Drug: CARRA/LNG containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: CARRA/LNG containing 1.5 mg LNG per 4 mL of gel
Study: 17519152
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of CARRA/LNG
Study: 15219640
Drug: Propranolol pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol pre-treatment
Study: 9642484
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (CCBs) with pravastatin (lipid-lowering therapy)
Study: 9642484
Drug: Pravastatin (lipid-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (lipid-lowering therapy)
Study: 2528022
Drug: Combined immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunosuppressive therapy (prednisone, cyclophosphamide, azathioprine)
Study: 2528022
Drug: Membrane plasmapheresis
Normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Membrane plasmapheresis (in addition to immunosuppressive therapy)
Study: 791477
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with disease confined to skin, subcutaneous tissue nodes, lung, or pleura
Study: 30037818
Drug: Ipatasertib 400
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib 400 mg with abiraterone 1,000 mg
Study: 30037818
Drug: Ipatasertib 200
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib 200 mg with abiraterone 1,000 mg
Study: 30037818
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with abiraterone 1,000 mg
Study: 24094463
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of AT-III 100 U/kg IV for 20 minutes
Study: 24094463
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of AT-III 100 U/kg IV for 20 minutes
Study: 18086050
Drug: smooth-gel hyaluronic
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: smooth-gel hyaluronic acid dermal fillers
Study: 11887498
Drug: Corticosteroids administered
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids administered systemically in the first two weeks after birth
Study: 9632998
Drug: Trimethoprim-sulfamethoxazole or
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole or alternative agents
Study: 7912876
Drug: Dixyrazine (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dixyrazine (15-30 mg)
Study: 7912876
Drug: Diazepam (4-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (4-10 mg)
Study: 2510135
Drug: Diltiazem 90
Normalized name: diltiazem 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 90 mg every 8 hours for 5 days
Study: 2510135
Drug: Encainide 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encainide 25 mg every 8 hours for 5 days
Study: 1254724
Drug: Gastrin antiserum
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrin antiserum (0.02, 0.1, and 0.5 ml/kg)
Study: 1254724
Drug: Gastrin antiserum
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrin antiserum (0.1 ml/kg)
Study: 1254724
Drug: Gastrin antiserum
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrin antiserum (0.2 ml/kg)
Study: 27045264
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg on-demand (PRN)
Study: 22998616
Drug: 1 implant
Normalized name: LEUPROLIDE ACETATE 72 MILLIGRAM In 1 IMPLANT SUBCUTANEOUS IMPLANT [Viadur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 implant (Group 1)
Study: 22998616
Drug: 2 implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 implants (Group 2)
Study: 10444231
Drug: Mizolastine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine (10 mg/day)
Study: 10444231
Drug: Mizolastine (5-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine (5-45 mg)
Study: 10444231
Drug: First generation
Normalized name: First generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: First generation antihistamines (clemastine, tripolidine) and second generation antihistamines (terfenadine, cetirizine)
Study: 1978488
Drug: Remoxipride (30-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (30-90 mg, 120-240 mg, 300-600 mg, divided into three doses per day)
Study: 1978488
Drug: Remoxipride (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (maximum dose for 4 weeks or more)
Study: 1978488
Drug: Remoxipride (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (dose reductions or discontinuations due to adverse symptoms)
Study: 31190491
Drug: Femoston (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoston (oral estradiol and dydrogesterone tablets)
Study: 29246219
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of Pycnogenol® twice daily
Study: 22097612
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 10 mg/d
Study: 16537846
Drug: Tiotropium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium plus formoterol once daily
Study: 16537846
Drug: Tiotropium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium plus formoterol twice daily
Study: 12492791
Drug: Bupivacaine 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 6.0 mg + fentanyl 25 micro g
Study: 12492791
Drug: Bupivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 7.5 mg + fentanyl 25 micro g
Study: 8095449
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 1 mg of terbutaline (4 puffs)
Study: 18484252
Drug: Extracorporal shock-wave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporal shock-wave therapy (ESWT)
Study: 8256187
Drug: Gentamicin 1.5
Normalized name: HYDROCORTISONE ACEPONATE 1.11 mg in 1 mL / MICONAZOLE NITRATE 17.4 mg in 1 mL / GENTAMICIN 1.5 mg in 1 mL AURICULAR (OTIC) SUSPENSION [EASOTIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 1.5 milligrams per kilogram IVPB plus clindamycin 0.9 grams every eight hours IVPB (G/C)
Study: 8256187
Drug: Gentamicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin plus clindamycin (G/C)
Study: 27325103
Drug: CO2 fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 fractional laser photothermolysis followed by 4 weeks topical application of B‐Resorcinol and Glycyrrhetinic acid
Study: 27325103
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of B‐Resorcinol and Glycyrrhetinic acid only
Study: 25411293
Drug: Daily 500
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily 500 μg vitamin B‐12 plus 400 μg folic acid supplementation for 2 years (including 600 IU vitamin D3)
Study: 25411293
Drug: Daily 500
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily 500 μg vitamin B‐12 plus 400 μg folic acid supplementation for 2 years
Study: 23290324
Drug: Metadoxine ER
Normalized name: metadoxine
DrugBank: Metadoxine (DB16554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metadoxine ER 1,400 mg/d for 6 weeks
Study: 18976162
Drug: Fentanyl 15
Normalized name: fentaNYL 150 mcg/30 mL-D5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 15 microg/kg + Ondansetron 12 mg
Study: 18976162
Drug: Fentanyl 12.5
Normalized name: FENTANYL 12.5MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 12.5 microg/kg + Ketorolac 1.5 mg/kg + Ondansetron 12 mg
Study: 18976162
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 microg/kg + Ketorolac 3 mg/kg + Ondansetron 12 mg
Study: 16096176
Drug: Gonadotropin releasing
Normalized name: Gonadotropin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin releasing hormone (GnRH, goserelin 3.6 mg) administered subcutaneously every 28 days for 12 weeks
Study: 11835027
Drug: Intravenous testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous testosterone (2 doses designed to increase testosterone 2 or 6 times baseline)
Study: 3034034
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg (3 times at 12-hour intervals)
Study: 3034034
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg daily for 2 weeks
Study: 27391675
Drug: Behavioural Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural Activation Treatment for Depression (Activate) - 10 individual 60-min therapy sessions with a psychologist, in addition to treatment as usual (TAU)
Study: 18658066
Drug: Language-Focused Curriculum
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Language-Focused Curriculum (LFC) implemented by treatment teachers for an academic year.
Study: 12888401
Drug: Oral presentation
Normalized name: Gas-X Prevention Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral presentation (8 sessions)
Study: 10573549
Drug: Atole (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atole (high energy, high protein supplement)
Study: 10573549
Drug: Fresco (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresco (low energy, no-protein supplement)
Study: 8767568
Drug: Preventive group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive group (100 mg tramadol at extubation + continuous infusion of 200 mg tramadol)
Study: 31079083
Drug: Acupuncture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture with Doin therapy
Study: 25590331
Drug: Public health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Public health intervention promoting expedited partner therapy (EPT) with free patient-delivered partner therapy (PDPT) available to clinicians.
Study: 23688367
Drug: Integrated Pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Pain Management Program (IPMP) for staff and residents, consisting of 8 weeks of activities including gardening therapy and physiotherapy exercise.
Study: 20027365
Drug: Tenoten and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoten and Tenoten (pediatric formulation)
Study: 17578751
Drug: Glucosamine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine (1500 mg per day)
Study: 15539864
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amitriptyline and citalopram
Study: 11314213
Drug: 3% benzalkonium
Normalized name: BENZALKONIUM CHLORIDE 5.2 mg TOPICAL CLOTH [Antiseptic sanitizing wipes (0.13% Benzalkonium Chloride)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% benzalkonium chloride solution
Study: 9503181
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus ticlopidine (250 mg)
Study: 10953
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol at a dose of 1 mg/kg
Study: 10953
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol at a dose of 2 mg/kg
Study: 10953
Drug: Intravenous labetalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous labetalol at a dose of 1 mg/kg and 2 mg/kg
Study: 31811662
Drug: Inhaled Technosphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Technosphere Insulin
Study: 31811662
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin aspart
Study: 18840027
Drug: Venlafaxine 37.5
Normalized name: venlafaxine 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5 mg
Study: 12574793
Drug: Delapril 30
Normalized name: Delapril
DrugBank: Delapril (DB13312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril 30 mg + Indapamide 1.25 mg (D+I)
Study: 12574793
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg + Hydrochlorothiazide 15 mg (C+H)
Study: 1545660
Drug: CAAD (diphenhydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAAD (diphenhydramine hydrochloride, 50 mg; pseudoephedrine hydrochloride, 60 mg; acetaminophen, 1 g in 10% ethanol)
Study: 1545660
Drug: Diphenhydramine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (single dose)
Study: 3872241
Drug: Endoscopic Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic Nd:YAG laser therapy
Study: 3872241
Drug: Sham endoscopy
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham endoscopy and standard medical therapy (Control)
Study: 24100705
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for back pain and VCF
Study: 22425507
Drug: Risedronate, 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate, 35 mg once weekly
Study: 20868284
Drug: Egg-derived trivalent
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg-derived trivalent inactivated vaccine (TIV)
Study: 19024795
Drug: Glabridin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glabridin (60 mg)
Study: 12879120
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic therapies
Study: 8973995
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg) with prednisone (40 mg)
Study: 8973995
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg) with prednisone (40 mg)
Study: 8973995
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with prednisone (40 mg)
Study: 1283847
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (single-agent tamoxifen)
Study: 1283847
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with endocrine therapy
Study: 1283847
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of chemotherapy with colony-stimulating factors and bone marrow transplantation
Study: 1283847
Drug: Combined endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined endocrine therapy
Study: 3931537
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + glibenclamide 5 mg twice daily
Study: 30646879
Drug: Group schema-focused
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group schema-focused therapy enriched with psychomotor therapy (SFT + PMT)
Study: 28597302
Drug: Pre-operative hypertension
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative hypertension treatment
Study: 23644914
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch applied to smokers during nicotine withdrawal
Study: 23644914
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch applied to smokers
Study: 23644914
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch applied to non-smokers
Study: 22333098
Drug: Marvelon (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marvelon (30 µg ethinylestradiol and 150 µg desogestrel) for 21 days
Study: 22333098
Drug: Progynova 2
Normalized name: Progynova 2 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progynova 2 mg/d for 21 days and depogesterone 10 mg/d for last 5 days
Study: 15303255
Drug: Ylang-ylang oil
Normalized name: Ylang-ylang oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ylang-ylang oil (Cananga odorata) inhalation
Study: 9813876
Drug: 20% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% glucose polymer (G)
Study: 3234614
Drug: Trimoprostil 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimoprostil 3 mg twice daily
Study: 3234614
Drug: Trimoprostil 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimoprostil 3 mg at bedtime
Study: 31821741
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of immunosuppressive drugs
Study: 26335087
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (DHA) 1,470 mg/d plus 147 mg/d of eicosapentaenoic acid (EPA)
Study: 23061976
Drug: T/LAIV (trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: T/LAIV (trivalent live attenuated influenza vaccine)
Study: 18354393
Drug: Depot leuprolide
Normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot leuprolide acetate (Lupron) every 4 weeks for 3 months (men) or 5 months (women) + testosterone enanthate (200 mg intramuscularly) every 2 weeks for 1 month (men)
Study: 17006278
Drug: Intranasal CAIV-T
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal CAIV-T (live attenuated cold-adapted influenza vaccine)